InvestorsHub Logo
Followers 0
Posts 14
Boards Moderated 0
Alias Born 12/21/2005

Re: antihama post# 1715

Thursday, 07/27/2017 9:47:13 AM

Thursday, July 27, 2017 9:47:13 AM

Post# of 3283
As antihama is looking forward to the breast cancer update of the korean study at ESMO 2017 i want to add one thought regarding the exon 20 mutation trial: pozitinib shrank tumors in vivo 85% for EGFR exon 20 and 60% for HER exon 20 mutation. So MD Anderson started with more promising EGFR exon 20 part. Recently they doubled the trial to include HER exon 20 mutations. So just think about it and use a little logic: They must have seen enough activity in EGFR exon 20 mutations otherwise they wouldn't have started the second cohort with HER exon 20 mutations.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent SPPI News